Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director | April 16, 2025 | April 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUCELL CORP /DE/
Report date April 16, 2025 · Filed April 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.49 · Expires 2030-04-16 | Direct | 10,000 |
Reported balance
After 2025-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-16 · Grant · Acquired 10,000 · Balance 10,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 12, 2025 21:09 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | PurchaseCommon stock $0.10 per value per share | 1,000 | $6.32 | $6,320.00 |
DisclosureSEC source: 0001213900-25-053904 · marketforms-69920.xml · nonDerivative · entry 1 Gathagan Bryan K. · CIK 0001981919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| April 16, 2025 Filed Apr 14, 2026 19:40 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001437749-26-012240 · rdgdoc.xml · derivative · entry 1 Gathagan Bryan K. · CIK 0001981919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-04-16 Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 12:29 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon-Qualified Stock Options (Right to buy) · Derivative | 10,000 | $3.60 Strike: $3.60 | $36,000.00 |
DisclosureSEC source: 0001213900-24-081206 · marketforms-67042.xml · derivative · entry 1 Gathagan Bryan K. · CIK 0001981919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-20 Read SEC document |
| June 28, 2023 Filed Aug 30, 2023 18:49 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon-Qualified Stock Options (Right to buy) · Derivative | 15,000 | $5.11 Strike: $5.11 | $76,650.00 |
DisclosureSEC source: 0001213900-23-072079 · marketforms-62425.xml · derivative · entry 1 Gathagan Bryan K. · CIK 0001981919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-28 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.